Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Microscopes and Telescopes: the Societal Impact of Substance Use Disorder Treatment.

Connery HS, Weiss RD.

Am J Psychiatry. 2018 Oct 1;175(10):925-926. doi: 10.1176/appi.ajp.2018.18060694. No abstract available.

PMID:
30269546
2.

Mortality in the United States from self-injury surpasses diabetes: a prevention imperative.

Rockett IRH, Caine ED, Connery HS, Greenfield SF.

Inj Prev. 2018 Aug 27. pii: injuryprev-2018-042889. doi: 10.1136/injuryprev-2018-042889. [Epub ahead of print]

3.

Variation in Deaths From Intentional Injury and Substance Use.

Rockett IRH, Connery HS.

JAMA. 2018 Aug 14;320(6):601. doi: 10.1001/jama.2018.7323. No abstract available.

PMID:
30120467
4.

Method overtness, forensic autopsy, and the evidentiary suicide note: A multilevel National Violent Death Reporting System analysis.

Rockett IRH, Caine ED, Stack S, Connery HS, Nolte KB, Lilly CL, Miller TR, Nelson LS, Putnam SL, Nestadt PS, Jia H.

PLoS One. 2018 May 22;13(5):e0197805. doi: 10.1371/journal.pone.0197805. eCollection 2018.

5.

Discerning suicide in drug intoxication deaths: Paucity and primacy of suicide notes and psychiatric history.

Rockett IRH, Caine ED, Connery HS, D'Onofrio G, Gunnell DJ, Miller TR, Nolte KB, Kaplan MS, Kapusta ND, Lilly CL, Nelson LS, Putnam SL, Stack S, Värnik P, Webster LR, Jia H.

PLoS One. 2018 Jan 10;13(1):e0190200. doi: 10.1371/journal.pone.0190200. eCollection 2018.

6.
7.

Religious coping in patients with severe substance use disorders receiving acute inpatient detoxification.

Medlock MM, Rosmarin DH, Connery HS, Griffin ML, Weiss RD, Karakula SL, McHugh RK.

Am J Addict. 2017 Oct;26(7):744-750. doi: 10.1111/ajad.12606. Epub 2017 Aug 24.

8.

Perceived barriers to smoking cessation among adults with substance use disorders.

McHugh RK, Votaw VR, Fulciniti F, Connery HS, Griffin ML, Monti PM, Weiss RD.

J Subst Abuse Treat. 2017 Mar;74:48-53. doi: 10.1016/j.jsat.2016.12.008. Epub 2016 Dec 30.

9.

Perceived risk of heroin use among nonmedical prescription opioid users.

Votaw VR, Wittenauer J, Connery HS, Weiss RD, McHugh RK.

Addict Behav. 2017 Feb;65:218-223. doi: 10.1016/j.addbeh.2016.08.025. Epub 2016 Aug 15.

10.

Predictors of early dropout in outpatient buprenorphine/naloxone treatment.

Marcovitz DE, McHugh RK, Volpe J, Votaw V, Connery HS.

Am J Addict. 2016 Sep;25(6):472-7. doi: 10.1111/ajad.12414. Epub 2016 Jul 21.

11.

Understanding HIV Risk Behavior among Tuberculosis Patients with Alcohol Use Disorders in Tomsk, Russian Federation.

Miller AC, Nelson AK, Livchits V, Greenfield SF, Yanova G, Yanov S, Connery HS, Atwood S, Lastimoso CS, Shin SS; Tomsk Tuberculosis Alcohol Working Group.

PLoS One. 2016 Feb 12;11(2):e0148910. doi: 10.1371/journal.pone.0148910. eCollection 2016.

12.

Training in Buprenorphine and Office-Based Opioid Treatment: A Survey of Psychiatry Residency Training Programs.

Suzuki J, Ellison TV, Connery HS, Surber C, Renner JA.

Acad Psychiatry. 2016 Jun;40(3):498-502. doi: 10.1007/s40596-015-0313-1. Epub 2015 May 28.

PMID:
26017618
13.

Medication-assisted treatment of opioid use disorder: review of the evidence and future directions.

Connery HS.

Harv Rev Psychiatry. 2015 Mar-Apr;23(2):63-75. doi: 10.1097/HRP.0000000000000075. Review.

PMID:
25747920
14.

Initial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent population.

McDermott KA, Griffin ML, Connery HS, Hilario EY, Fiellin DA, Fitzmaurice GM, Weiss RD.

J Clin Psychiatry. 2015 Feb;76(2):189-94. doi: 10.4088/JCP.14m09096.

15.

Denial of urinalysis-confirmed opioid use in prescription opioid dependence.

Hilario EY, Griffin ML, McHugh RK, McDermott KA, Connery HS, Fitzmaurice GM, Weiss RD.

J Subst Abuse Treat. 2015 Jan;48(1):85-90. doi: 10.1016/j.jsat.2014.07.003. Epub 2014 Jul 18.

16.

Preliminary survey of office-based opioid treatment practices and attitudes among psychiatrists never receiving buprenorphine training to those who received training during residency.

Suzuki J, Connery HS, Ellison TV, Renner JA.

Am J Addict. 2014 Nov-Dec;23(6):618-22. doi: 10.1111/j.1521-0391.2014.12143.x. Epub 2014 Jul 25.

17.

Group therapy for women with substance use disorders: results from the Women's Recovery Group Study.

Greenfield SF, Sugarman DE, Freid CM, Bailey GL, Crisafulli MA, Kaufman JS, Wigderson S, Connery HS, Rodolico J, Morgan-Lopez AA, Fitzmaurice GM.

Drug Alcohol Depend. 2014 Sep 1;142:245-53. doi: 10.1016/j.drugalcdep.2014.06.035. Epub 2014 Jul 4.

18.

It's MORe exciting than mu: crosstalk between mu opioid receptors and glutamatergic transmission in the mesolimbic dopamine system.

Chartoff EH, Connery HS.

Front Pharmacol. 2014 May 27;5:116. doi: 10.3389/fphar.2014.00116. eCollection 2014. Review.

19.

Substance abuse during pregnancy.

Connery HS, Rayburn WF.

Obstet Gynecol Clin North Am. 2014 Jun;41(2):xiii-xiv. doi: 10.1016/j.ogc.2014.02.003. Epub 2014 Mar 27. No abstract available.

PMID:
24845495
20.

Adolescent substance use and unplanned pregnancy: strategies for risk reduction.

Connery HS, Albright BB, Rodolico JM.

Obstet Gynecol Clin North Am. 2014 Jun;41(2):191-203. doi: 10.1016/j.ogc.2014.02.011. Epub 2014 Apr 6. Review.

21.

Who benefits from additional drug counseling among prescription opioid-dependent patients receiving buprenorphine-naloxone and standard medical management?

Weiss RD, Griffin ML, Potter JS, Dodd DR, Dreifuss JA, Connery HS, Carroll KM.

Drug Alcohol Depend. 2014 Jul 1;140:118-22. doi: 10.1016/j.drugalcdep.2014.04.005. Epub 2014 Apr 24.

22.

Implementing substance abuse group therapy clinical trials in real-world settings: challenges and strategies for participant recruitment and therapist training in the Women's Recovery Group Study.

Greenfield SF, Crisafulli MA, Kaufman JS, Freid CM, Bailey GL, Connery HS, Rapoza M, Rodolico J.

Am J Addict. 2014 May-Jun;23(3):197-204. doi: 10.1111/j.1521-0391.2014.12099.x.

23.

Association of cannabis use with opioid outcomes among opioid-dependent youth.

Hill KP, Bennett HE, Griffin ML, Connery HS, Fitzmaurice GM, Subramaniam G, Woody GE, Weiss RD.

Drug Alcohol Depend. 2013 Sep 1;132(1-2):342-5. doi: 10.1016/j.drugalcdep.2013.02.030. Epub 2013 Mar 22.

24.

Effectiveness of alcohol treatment interventions integrated into routine tuberculosis care in Tomsk, Russia.

Shin S, Livchits V, Connery HS, Shields A, Yanov S, Yanova G, Fitzmaurice GM, Nelson AK, Greenfield SF; Tomsk Tuberculosis Alcohol Working Group.

Addiction. 2013 Aug;108(8):1387-96. doi: 10.1111/add.12148. Epub 2013 May 13.

25.

Gender differences in a clinical trial for prescription opioid dependence.

McHugh RK, Devito EE, Dodd D, Carroll KM, Potter JS, Greenfield SF, Connery HS, Weiss RD.

J Subst Abuse Treat. 2013 Jul;45(1):38-43. doi: 10.1016/j.jsat.2012.12.007. Epub 2013 Jan 11.

26.

Diagnosing and treating opioid dependence.

Hill KP, Rice LS, Connery HS, Weiss RD.

J Fam Pract. 2012 Oct;61(10):588-97. Review.

PMID:
23106060
27.

Implementing evidence-based alcohol interventions in a resource-limited setting: novel delivery strategies in Tomsk, Russia.

Shin SS, Livchits V, Nelson AK, Lastimoso CS, Yanova GV, Yanov SA, Mishustin SP, Connery HS, Greenfield SF.

Harv Rev Psychiatry. 2012 Jan-Feb;20(1):58-67. doi: 10.3109/10673229.2012.649121.

28.

Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.

Weiss RD, Potter JS, Fiellin DA, Byrne M, Connery HS, Dickinson W, Gardin J, Griffin ML, Gourevitch MN, Haller DL, Hasson AL, Huang Z, Jacobs P, Kosinski AS, Lindblad R, McCance-Katz EF, Provost SE, Selzer J, Somoza EC, Sonne SC, Ling W.

Arch Gen Psychiatry. 2011 Dec;68(12):1238-46. doi: 10.1001/archgenpsychiatry.2011.121. Epub 2011 Nov 7.

29.

Alcohol consumption among men and women with tuberculosis in Tomsk, Russia.

Shin SS, Mathew TA, Yanova GV, Fitzmaurice GM, Livchits V, Yanov SA, Strelis AK, Mishustin SP, Bokhan NA, Lastimoso CS, Connery HS, Hart JE, Greenfield SF.

Cent Eur J Public Health. 2010 Sep;18(3):132-8.

30.

HIV risk behavior in treatment-seeking opioid-dependent youth: results from a NIDA clinical trials network multisite study.

Meade CS, Weiss RD, Fitzmaurice GM, Poole SA, Subramaniam GA, Patkar AA, Connery HS, Woody GE.

J Acquir Immune Defic Syndr. 2010 Sep;55(1):65-72. doi: 10.1097/QAI.0b013e3181d916db.

31.

A multi-site, two-phase, Prescription Opioid Addiction Treatment Study (POATS): rationale, design, and methodology.

Weiss RD, Potter JS, Provost SE, Huang Z, Jacobs P, Hasson A, Lindblad R, Connery HS, Prather K, Ling W.

Contemp Clin Trials. 2010 Mar;31(2):189-99. doi: 10.1016/j.cct.2010.01.003. Epub 2010 Jan 29.

32.

Integrated Management of Physician-delivered Alcohol Care for Tuberculosis Patients: Design and Implementation.

Greenfield SF, Shields A, Connery HS, Livchits V, Yanov SA, Lastimoso CS, Strelis AK, Mishustin SP, Fitzmaurice G, Mathew TA, Shin S.

Alcohol Clin Exp Res. 2010 Feb;34(2):317-30. doi: 10.1111/j.1530-0277.2009.01094.x. Epub 2009 Nov 20.

33.

Treatment of patients with substance use disorders, second edition. American Psychiatric Association.

Kleber HD, Weiss RD, Anton RF Jr, George TP, Greenfield SF, Kosten TR, O'Brien CP, Rounsaville BJ, Strain EC, Ziedonis DM, Hennessy G, Connery HS, McIntyre JS, Charles SC, Anzia DJ, Cook IA, Finnerty MT, Johnson BR, Nininger JE, Summergrad P, Woods SM, Yager J, Pyles R, Cross CD, Peele R, Shemo JP, Lurie L, Walker RD, Barnovitz MA, Gray SH, Saxena S, Tonnu T, Kunkle R, Albert AB, Fochtmann LJ, Hart C, Regier D; Work Group on Substance Use Disorders; American Psychiatric Association; Steering Committee on Practice Guidelines.

Am J Psychiatry. 2007 Apr;164(4 Suppl):5-123. Review. No abstract available.

PMID:
17569411
34.

The relationship of self-esteem and self-efficacy to treatment outcomes of alcohol-dependent men and women.

Trucco EM, Connery HS, Griffin ML, Greenfield SF.

Am J Addict. 2007 Mar-Apr;16(2):85-92.

PMID:
17453609
35.

Treatment of patients with substance use disorders, second edition. American Psychiatic Association.

Work Group on Substance Use Disorders, Kleber HD, Weiss RD, Anton RF, Rounsaville BJ, George TP, Strain EC, Greenfield SF, Ziedonis DM, Kosten TR, Hennessy G, O'Brien CP, Connery HS; American Psychiatric Association Steering Committee on Practice Guidelines, McIntyre JS, Charles SC, Anzia DJ, Nininger JE, Cook IA, Summergrad P, Finnerty MT, Woods SM, Johnson BR, Yager J, Pyles R, Lurie L, Cross CD, Walker RD, Peele R, Barnovitz MA, Gray SH, Shemo JP, Saxena S, Tonnu T, Kunkle R, Albert AB, Fochtmann LJ, Hart C, Regier D.

Am J Psychiatry. 2006 Aug;163(8 Suppl):5-82. No abstract available. Erratum in: Am J Psychiatry. 2006 Oct;163(10):1843.

PMID:
16981488
36.
37.

Further validation of the Psycho-Social Well-Being Scale (PSWS) with community clients.

O'Hare T, Sherrer MV, Connery HS, Thornton J, LaButti A, Emrick K.

Community Ment Health J. 2003 Apr;39(2):115-29.

PMID:
12723846
38.

Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs.

Kilts JD, Connery HS, Arrington EG, Lewis MM, Lawler CP, Oxford GS, O'Malley KL, Todd RD, Blake BL, Nichols DE, Mailman RB.

J Pharmacol Exp Ther. 2002 Jun;301(3):1179-89.

PMID:
12023553
39.

Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase.

Mottola DM, Kilts JD, Lewis MM, Connery HS, Walker QD, Jones SR, Booth RG, Hyslop DK, Piercey M, Wightman RM, Lawler CP, Nichols DE, Mailman RB.

J Pharmacol Exp Ther. 2002 Jun;301(3):1166-78.

PMID:
12023552

Supplemental Content

Loading ...
Support Center